Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Thoracic 1Gynecologic 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 63Leukemia, Myeloid, Acute 31Leukemia 25Carcinoma, Renal Cell 23Lymphoma 21Kidney Neoplasms 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Neoplasm Metastasis 14Lymphoma, Mantle-Cell 13Myelodysplastic Syndromes 12Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 12Leukemia, Lymphocytic, Chronic, B-Cell 12Neuroblastoma 11Ovarian Neoplasms 10Congenital Abnormalities 10Lymphoma, B-Cell, Marginal Zone 9Breast Neoplasms 9Multiple Myeloma 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Stomach Neoplasms 7Recurrence 7Lymphoma, Large B-Cell, Diffuse 7Burkitt Lymphoma 7Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Skin Neoplasms 5Pancreatic Neoplasms 5Myeloproliferative Disorders 5

Interventions

Cyclophosphamide 10fludarabine 5Radiotherapy 5Doxorubicin 5Gemcitabine 3sargramostim 2fludarabine phosphate 2aldesleukin 2Sunitinib 2Radiation Dose Hypofractionation 2Nivolumab 2Leukapheresis 2Ifosfamide 2Docetaxel 2Decitabine 2Dacarbazine 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2trofosfamide 1tremelimumab 1temsirolimus 1sotigalimab 1ribociclib 1poly ICLC 1pembrolizumab 1pegfilgrastim 1pazopanib 1pasireotide 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Sarcoma, Synovial × aldesleukin × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT03450122 2023-10-16

Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
Sarcoma

Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡